Eli Lilly's GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list.Yahoo Finance Senior Health Reporter Anjalee Khemlani ...

Donanemab, manufactured by Eli Lilly (LLY), is the latest in a new class of anti-amyloid drugs that deliver antibodies to target beta-amyloid, a protein linked to Alzheimer's disease. Initially ...

The most recent trading session ended with Eli Lilly (LLY) standing at $909.32, reflecting a -1.65% shift from the previouse trading day's closing. This change lagged the S&P 500's daily gain of 0.4%.

“So, I would take him at his word,” he added. The remarks followed a conversation in which, according to Coppins, it became clear Romney had spent some time thinking about Trump’s threats to ...

Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure they stay there as competition enters, the companies are spending billions in ...

Travis Gettys is a senior editor for Raw Story based in northern Kentucky. He previously worked as a web editor for WLWT-TV and a contributing writer for the Kentucky Enquirer, and he also wrote ...

Sept 24 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing patients with another treatment ...

New public and private entrants are emerging to challenge the leading positions of Novo Nordisk NVO and Eli Lilly LLY in a potential $200 billion total GLP-1 market, which we expect will see 68% ...

Eli Lilly's long-term growth prospects have been secured by the improved supply in H2'24 and the incoming capacity additions from H1'25 onwards. This is on top of the introduction of its D2C ...

Eli Lilly has become a household name thanks to breakthrough diabetes and obesity care medicines. The stock has trounced the broader market over the past year, and shares have become a bit pricey.

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,150.00. Alec Stranahan ...

Compounding pharmacies have used a legal provision that allows them to make knockoff versions of Lilly’s Zepbound and Mounjaro while they are in a shortage. While Lilly has raised questions about the ...